Literature DB >> 9659240

Telomerase expression shows differences across multiple regions of oligodendroglioma versus high grade astrocytomas but shows correlation with Mib-1 labelling.

B K Kleinschmidt-DeMasters1, T L Hashizumi, C I Sze, K O Lillehei, A L Shroyer, K R Shroyer.   

Abstract

AIMS/
BACKGROUND: Telomerase is an enzyme that is expressed in most human neoplasms and is associated with tumour immortality. Determination of the point in neoplastic transformation at which telomerase is expressed may aid the understanding of tumour pathogenesis and progression. Despite numerous reports on telomerase, few studies have investigated its expression in high grade glial tumours. These studies, performed on archival banked, single brain tumour specimens, have shown conflicting results for oligodendrogliomas and unexpectedly negative results for telomerase expression in high grade astrocytomas, with one third to one half of glioblastoma multiformes being negative.
METHODS: 34 rapidly banked glioma specimens taken from patients undergoing gross total surgical resection of their tumours were studied. Telomerase expression was assessed across 3-8 sampled regions from each tumour by the telomeric repeat amplification protocol (TRAP) assay. Matched mirror image tissue samples were taken for histological analysis of tissue adequacy, statistical correlation of telomerase with tumour histological features, Mib-1 (a marker for cell cycling) labelling, and p53 immunohistochemistry.
RESULTS: All five well differentiated oligodendrogliomas were homogeneously telomerase negative and two of three untreated anaplastic oligodendrogliomas were homogeneously positive. In contrast, 10 of 14 high grade astrocytomas showed heterogeneity for telomerase expression across the multiple regions sampled. All glioblastoma multiformes and two of three anaplastic astrocytomas showed at least one region positive for telomerase. When test samples were individually assessed in both oligodendrogliomas and high grade astrocytomas, telomerase expression was associated with Mib-1 labelling (p < 0.001). For the entire group, telomerase expression was associated with grade of tumour, age of patient, and vascular endothelial proliferation (all p < 0.001).
CONCLUSIONS: This regional study clarifies that all glioblastoma multiformes are at least focally positive and that telomerase expression correlates with tumour grade in oligodendrogliomas. Homogeneity versus heterogeneity for telomerase expression across multiple regions of oligodendrogliomas versus high grade astrocytomas may provide important preclinical data on the use of antitelomerase agents in these adult glial tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659240      PMCID: PMC500671          DOI: 10.1136/jcp.51.4.284

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Telomerase activity concentrates in the mitotically active segments of human hair follicles.

Authors:  R D Ramirez; W E Wright; J W Shay; R S Taylor
Journal:  J Invest Dermatol       Date:  1997-01       Impact factor: 8.551

3.  Up-regulation of telomerase activity in human lymphocytes.

Authors:  O Yamada; T Motoji; H Mizoguchi
Journal:  Biochim Biophys Acta       Date:  1996-12-12

4.  Telomeres, telomerase and cancer.

Authors:  C W Greider; E H Blackburn
Journal:  Sci Am       Date:  1996-02       Impact factor: 2.142

5.  Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.

Authors:  J M Kros; W C Hop; J J Godschalk; K K Krishnadath
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

6.  Of telomeres and tumors.

Authors:  N Axelrod
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

7.  Telomerase activity in human breast tumors.

Authors:  E Hiyama; L Gollahon; T Kataoka; K Kuroi; T Yokoyama; A F Gazdar; K Hiyama; M A Piatyszek; J W Shay
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

8.  Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis.

Authors:  M A Blasco; M Rizen; C W Greider; D Hanahan
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

9.  Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications.

Authors:  P C Burger; F S Vogel; S B Green; T A Strike
Journal:  Cancer       Date:  1985-09-01       Impact factor: 6.860

10.  Detection of telomerase activity in malignant and nonmalignant skin conditions.

Authors:  R S Taylor; R D Ramirez; M Ogoshi; M Chaffins; M A Piatyszek; J W Shay
Journal:  J Invest Dermatol       Date:  1996-04       Impact factor: 8.551

View more
  4 in total

1.  Telomerase expression in uveal melanoma.

Authors:  B Heine; S E Coupland; S Kneiff; G Demel; N Bornfeld; M Hummel; H Stein
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 2.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

3.  Telomerase activity in human brain tumors: astrocytoma and meningioma.

Authors:  Majid Kheirollahi; Masoud Mehrazin; Naser Kamalian; Javad Mohammadi-asl; Parvin Mehdipour
Journal:  Cell Mol Neurobiol       Date:  2013-03-20       Impact factor: 5.046

4.  Telomere length modulation in human astroglial brain tumors.

Authors:  Domenico La Torre; Alfredo Conti; M Hammed Aguennouz; Maria Grazia De Pasquale; Sara Romeo; Filippo Flavio Angileri; Salvatore Cardali; Chiara Tomasello; Concetta Alafaci; Antonino Germanò
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.